Alzheon Lands $47M to Take Another Shot at a Pivotal Alzheimer’s Test
Summary
The cash, a five-year grant from the NIH’s National Institute on Aging, represents another shot for the company and its drug, ALZ-801, which has previously failed in clinical trials. But the Framingham, MA-based biotech now plans to test its drug in a narrower group: patients who have are in the early stages of Alzheimer’s and also have two copies of APOE4/4, a genetic variant associated with a higher risk of developing the disease. The Alzheon drug is a reformulated version of tramiprosate, which was initially developed and tested by Montreal-based Neurochem, a company now known as Bellus Health (NASDAQ: BLU). The Phase 3 study is designed to enroll 300 patients who will be randomly assigned to receive the Alzheon pill or a placebo twice a day for 18 months. The study will also track biological indicators, including the levels of amyloid and tau proteins in the blood and cerebrospinal fluid.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
